Low immunogenicity of Avelumab, an immune checkpoint inhibititor demonstrating antitumor activity

Dr. Joleen White of EMD Serono provides case study data on Avelumab, an anti-PD-L1 antibody and details the safety assessment from Phase I/Ib and Phase II studies.